Winter ready, ultra cozy

Your holiday season match made in heaven  ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ͏  ͏  ͏  ͏  ͏  ͏­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­

SHOP LEATHER SKATE

Cariuma Central Pte Ltd   135 Cecil Street #10-01 MYP Plaza Singapore   Singapore 069536   Unsubscribe

Express Shipping Cutoff - Today! Shop Now

Get your order delivered by Christmas  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  Swanky Badger | 925 Poinsettia Ave Unit 14 Vista, CA 92081 Time to part ways? Unsubscribe ©2023 Swanky Badger

A Ground-floor Biotech with Enormous Potential

Unsubscribe       Weight loss pharmaceuticals have made investors millions this year.   Drugs like Ozempic and Wegovy have generated tremendous buzz, and guess what? This clinical stage biotech company may have the next BETTER thing in the works.   The popularity of Ozempic and Wegovy has translated into rapid sales growth for Novo Nordisk and Eli Lilly. Yet, studies have shown that these drugs could lead to a significant decrease in muscle mass. Also, the results may not be long-lasting— if patients go off the drug.   The solution? That's what this biotech is working on.   With its leading effort to realize the pharmaceutical potential of endocannabinoid receptors, this CB1 biotech is entering an important stage of its development— a key stage for investors.   If its upcoming clinical trial is successful, there could be INCREDIBLE upside— coming very soon.   See how this company could safely tackle weight-loss before everyone else takes note.     (By clicking the link above, you are opting in to receive emails from this advertiser . You are also agreeing to the terms of our privacy policy. Unsubscribe at any time)

This email was sent to stevenmagallanes520.nims@blogger.com by editor@marketmovingtrends.com CLM LLC c/o MarketMovingTrends, 45 South Park Place, #203, Morristown, NJ 07960 United States   Unsubscribe | Report Spam

The upside potential for this biotech company is at over 200% with a $9.25 price target!

Zack's Small Cap Research thinks this company is "underpriced" and gave it a $9.25 price target! Regenerative medicine is the future, and it comes as no surprise that the biotech space is all over it. Who will be the leading biotech companies utilizing regenerative medicine in the future? That's the million-dollar question but this emerging company has explosive growth potential ahead in this rising arena. The company is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. These allografts are not just any allografts. They are best-in-class perinatal tissue allografts! The company is focused on the diabetic wound care market and the advanced wound care market: two multi-billion-dollar markets that could equate to explosive revenues all while helping patients. Recently the company reported a stellar third quarter where net revenue grew over 200% and gross profit grew 79%! Revenues are skyrocketing, the company has secured a CMS Q code, there are game-changing partnerships, a successful capital raise, and the start of a crucial clinical trial for diabetic foot ulcers… this all reads like a recipe for tremendous shareholder value! Learn how this little-known company may soon become the next biotech darling!

---

This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1,000. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM).

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com

Retire on this 1 ticker?

  Smoky Mountain Grandma Reveals
Brand New "One Ticker Income Plan"

A "backwoods Grandma" who turned an $800 stake into a steady source of income is revealing a brand new trading strategy.

It takes just 1 ticker...

... and a few minutes a week.

The Exact Ticker Symbol Revealed Here

P.S. There's approximately 3,550 stocks available for trading but you can ignore 3,549 of 'em when you click to reveal this 1 ticker symbol...

 

---

 

© 2023 Tradewins Publishing. All rights reserved. | Privacy Policy | Terms and Conditions | Contact Us

The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the "Services") is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by Universal Financial Independence Inc., ("Universal") a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk and is not appropriate for everyone. The actual profit results presented here may vary with the actual profit results presented in other Universal Financial Independence, Inc. publications due to the different strategies and time frames presented in other publications. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, Universal does not make any guarantee or other promise as to any results that may be obtained from using the Services. Universal disclaims any and all liability for any investment or trading loss sustained by a subscriber. You should trade or invest only "risk capital" - money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses.

Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Universal makes no representations or warranties that any account will or is likely to achieve profits similar to those shown. No representation is being made that you will achieve profits or the same results as any person providing a testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have subsequently experienced losses. Wendy Kirkland's experiences are not typical. Wendy Kirkland is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position, willingness to follow the rules and other factors.

You are currently subscribed to tradewins as: stevenmagallanes520.nims@blogger.com. Add wendy@tradewins.com to your email address book to ensure delivery. Forward to a Friend | Manage Subscription | Subscribe | Unsubscribe | Snooze